Series A to B: Sequoia Signal

OpenEvidence just hit a $12 billion valuation — here's the full story of how it happened. Daniel Nadler sold his first company, Kensho, to S&P Global for $550 million. Then he turned his attention to one of the most broken systems in the world — medical information.

Hosts Roupen Odabashian, MD and Osama Hyder break down the full story of OpenEvidence — the AI-powered clinical decision support platform now used by 40% of US physicians, handling 358,000 queries per day.

We cover Daniel's origin story from Toronto to Harvard PhD, the Federal Reserve, and the founding of Kensho in 2013. We explore the $550M S&P acquisition, his parallel career as a published poet and MoMA PS1 board member, co-founder Zachary Ziegler's background, the Mayo Clinic partnership, domain-specific AI architecture, the USMLE 100% score debate, and the explosive growth that followed.

The second half dives into the funding roadmap (Series A–D), product expansion into AI Scribe and DeepConsult, the direct-to-physician business model, monetization strategy, competitive analysis, network effects, and bear case risks.

Whether you're a physician, a health tech founder, or an AI investor — this is the most in-depth breakdown of OpenEvidence you'll find anywhere.

Subscribe for weekly deep dives: deltahealth.tech | Sponsored by PMWC 2026 — use code DELTAHEALTH at pmwcintl.com

Timestamps: 00:00 - Hook: Who is Daniel Nadler & Why OpenEvidence Matters 01:46 - Welcome & Host Introductions 05:48 - Daniel Nadler's Origin Story 12:10 - Harvard PhD & The Federal Reserve 17:00 - Founding Kensho Technologies (2013) 22:00 - S&P Global Acquires Kensho for $550M 29:38 - Poetry & Art Career (MoMA PS1) 31:29 - The Information Crisis in Medicine 48:25 - The Founding of UpToDate 1:02:26 - ChatGPT Launches (November 2022) 1:15:00 - Zachary Ziegler's Background 1:21:00 - Self-Funding & Founding OpenEvidence 1:27:46 - The Mayo Clinic Partnership 1:34:46 - Technical Architecture: AI, RAG & Citations 1:46:00 - USMLE 100% Score & The Debate 1:53:30 - Growth: 358,000 Queries Per Day 2:08:00 - Funding Roadmap: Series A Through D 2:40:00 - Future of AI & The Physician Relationship 2:45:17 - Product Expansion: AI Scribe & DeepConsult 3:05:00 - Direct-to-Physician Approach 3:17:20 - Business Model & Monetization 3:32:15 - Competitive Analysis & Network Effects 3:47:00 - Bear Case & Risks

Hosts: Roupen Odabashian: roupen@deltahealth.tech | linkedin.com/in/roupen-odabashian-md-frcpc-fasco-183aaa142 Osama Hyder: osama@deltahealth.tech | linkedin.com/in/sam-hyder